|
|
|
|
|
|
|
||
J. Exp. Med.,
Volume 189, Number 10, May 17, 1999 1659-1668
By
From the Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda,
Maryland 20892
CD4+ T cells play an important role in antitumor immune responses and autoimmune and infectious diseases. Although many major histocompatibility complex (MHC) class I-restricted
tumor antigens have been identified in the last few years, little is known about MHC class II-
restricted human tumor antigens recognized by CD4+ T cells. Here, we describe the identification of a novel melanoma antigen recognized by an human histocompatibility leukocyte antigen (HLA)-DR1-restricted CD4+ tumor-infiltrating lymphocyte (TIL)1363 using a genetic
cloning approach. DNA sequencing analysis indicated that this was a fusion gene generated by
a low density lipid receptor (LDLR) gene in the 5' end fused to a GDP-L-fucose:
-D-galactoside 2-
-L-fucosyltransferase (FUT) in an antisense orientation in the 3' end. The fusion gene encoded the first five ligand binding repeats of LDLR in the NH2 terminus followed by a new
polypeptide translated in frame with LDLR from the FUT gene in an antisense direction.
Southern blot analysis showed that chromosomal DNA rearrangements occurred in the
1363mel cell line. Northern blot analysis detected two fusion RNA transcripts present only in
the autologous 1363mel, but not in other cell lines or normal tissues tested. Two minimal peptides were identified from the COOH terminus of the fusion protein. This represents the first
demonstration that a fusion protein resulting from a chromosomal rearrangement in tumor cells
serves as an immune target recognized by CD4+ T cells.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
| TABLE OF CONTENTS |
|
